Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 18/20 | 0.79 |
| ▸ | CCR5 | P51681 | 1/20 | 0.61 |
| ▸ | EDNRA | P25101 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5764131 | 0.88 | CCR4 (1.00) | CCR4EDNRA | |
| SCHEMBL5764308 | 0.87 | CCR4 (0.80) | CCR4CCR5EDNRA | |
| SCHEMBL5763164 | 0.82 | CCR4 (0.70) | CCR4CCR5EDNRA | |
| SCHEMBL6072243 | 0.82 | CCR4 (1.00) | CCR4CCR5 | |
| SCHEMBL5111837 | 0.79 | CCR4 (1.00) | CCR4CCR5EDNRA | |
| SCHEMBL6182590 | 0.79 | CCR4 (0.72) | CCR4CCR5EDNRA | |
| SCHEMBL1731359 | 0.78 | CCR4 (1.00) | CCR4CCR5EDNRA | |
| SCHEMBL1732805 | 0.77 | CCR4 (1.00) | CCR4EDNRA | |
| SCHEMBL5111839 | 0.77 | CCR4 (1.00) | CCR4CCR5EDNRA | |
| SCHEMBL5105223 | 0.76 | CCR4 (1.00) | CCR4CCR5EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060128723-A1 | Sulptionamide compounds that modulate chemokine receptor activity (CCR4) | ASTRAZENECA AB (SE) | 2006-06-15 | — | — | US | claimed |
| US-20060128723-A1 | Sulptionamide compounds that modulate chemokine receptor activity (CCR4) | ASTRAZENECA AB (SE) | 2006-06-15 | — | — | US | disclosed |
| EP-1633744-A1 | SULPTIONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | AstraZeneca AB (SE) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004108717-A1 | SULPTIONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128723-A1 | Sulptionamide compounds that modulate chemokine receptor activity (CCR4) | CCR4, CCR3, CCR1 | CCR4 1/4885CCR5 5/4885EDNRA 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.